Loading patent…
AssigneeAmira Pharmaceuticals, Inc.
InventorsMelissa Virginia REWOLINSKI, Kevin Murray SCHAAB, Christopher David KING, Jillian F. EVANS, Petpiboon Peppi PRASIT, John Howard HUTCHINSON, Nicholas Simon STOCK
Estimating the term…
Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.
A pharmaceutical composition comprising:
An oral solid dosage form pharmaceutical composition comprising:
A pharmaceutical composition that provides to a mammal at least one compound selected from among:
A pharmaceutical composition comprising an active ingredient that inhibits 5-lipoxygenase-activating protein (FLAP) and does not inhibit at least one Cytochrome P450 enzyme selected from CYP 3A4, CYP 1A2, CYP 2A6, CYP 2B6, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, and CYP 2E1 at doses up to 50 μM.
A pharmaceutically acceptable salt of 3-[(5-pyridin-2ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]indol-2-yl]-2,2-dimethyl-propionic acid or pharmaceutically acceptable solvate thereof.
A crystalline form of sodium 3-[(5-pyridin-2ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionate or pharmaceutically acceptable solvate thereof.
A process for the preparation of sodium 3-[(5-pyridin-2ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]indol-2-yl]-2,2-dimethyl-propionate comprising the steps of:
Dependencies are inferred from the claim text.